Orchestra BioMed Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 10, 2023 and accepted by EDGAR at Aug 10, 2023, 16:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $915.0k | us-gaap:Revenues |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $2.1m | us-gaap:Revenues |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $54.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $98.0k | us-gaap:CostOfRevenue |
| Research and development | 3 months2023-04-01 to 2023-06-30 | $8.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-06-30 | $16.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-04-01 to 2023-06-30 | $5.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-01-01 to 2023-06-30 | $9.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$13.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$24.5m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$12.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$23.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | −$0.35 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | −$0.74 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | −$0.35 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | −$0.74 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 34,613,466 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 31,228,323 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | −$24.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $62.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-06-30 | $16.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $119.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $125.9m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $11.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $36.4m | us-gaap:Liabilities |
| Long-term debt | At period end2023-06-30 | $10.0m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2023-06-30 | $89.4m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0001558370-23-014496. Last ingested by Listed: Nov 2, 2026, 11:52 ET. Listed shows no prices and gives no investment advice.